Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a disclosure stating that its stock trading was temporarily suspended at 07:45 KST on May 22, 2025, due to a material disclosure (corporate spin-off decision), and was subsequently lifted at 09:30 KST on the same day following the release of the disclosure.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Trading Suspension and Lifting of Suspension (Material Disclosure)
- Target Security: Samsung Biologics Co., Ltd. Common Stock
- Type of Suspension: Trading suspension related to material information disclosure
- Trading Suspension Date & Time: May 22, 2025, at 07:45 KST
- Trading Suspension Lifting Date & Time: May 22, 2025, at 09:30 KST
- Reason for Suspension: Material information disclosure (Decision on corporate spin-off)
- Governing Rule: Article 40 of the KOSPI Market Disclosure Regulations
- Derivatives Market Notice: Stock futures and options on the underlying equity were simultaneously suspended in accordance with the equity market measure.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Lifting of Trading Suspension and Spin-off Progress
This disclosure provides notice that the temporary trading suspension placed on Samsung Biologics’ stock due to a material corporate announcement (spin-off decision) has been lifted and normal trading has resumed.
Reviewing the details within the disclosure on the corporate spin-off decision and monitoring subsequent milestones in the spin-off process is essential.
Relevant details can be verified in the Decision on Corporate Spin-off filed on the same date and in future official disclosures.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
